PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23169348-1 2013 Cannabinoid-1 receptors (CB(1)) have an important role in nicotine reward and their function is disrupted by chronic nicotine exposure, suggesting nicotine-induced alterations in endocannabinoid (eCB) signaling. Nicotine 58-66 cannabinoid receptor 1 Homo sapiens 0-23 33369277-0 2021 The CB1R rs2023239 receptor gene variant significantly affects the reinforcing effects of nicotine, but not cue reactivity, in human smokers. Nicotine 90-98 cannabinoid receptor 1 Homo sapiens 4-8 33369277-1 2021 INTRODUCTION: The cannabinoid CB1 receptor (CB1R) has been shown in preclinical studies to be involved in nicotine reinforcement and relapse-like behavior. Nicotine 106-114 cannabinoid receptor 1 Homo sapiens 30-42 33369277-1 2021 INTRODUCTION: The cannabinoid CB1 receptor (CB1R) has been shown in preclinical studies to be involved in nicotine reinforcement and relapse-like behavior. Nicotine 106-114 cannabinoid receptor 1 Homo sapiens 44-48 33369277-2 2021 The common single nucleotide polymorphism (SNP) rs2023239 may code for an alternative CB1R protein, alter CB1R expression, and be involved in nicotine dependence. Nicotine 142-150 cannabinoid receptor 1 Homo sapiens 86-90 33369277-3 2021 To date, no study has explored the relationship between this SNP in CB1R and specific phenotypes of nicotine dependence. Nicotine 100-108 cannabinoid receptor 1 Homo sapiens 68-72 33369277-4 2021 METHODS: The current study investigated the influence of CB1R rs2023239 in nicotine reinforcement and craving in regular cigarette smokers. Nicotine 75-83 cannabinoid receptor 1 Homo sapiens 57-61 33369277-10 2021 CONCLUSION: Taken together, these results suggest that the variation in the CB1R (i.e., rs2023239 SNP) may play a larger role in nicotine reinforcement compared to cue reactivity. Nicotine 129-137 cannabinoid receptor 1 Homo sapiens 76-80 25859226-3 2015 The CB1 receptor inverse agonist/antagonist rimonabant (also known as SR141716) was effective to decrease nicotine-taking and nicotine-seeking in rodents, as well as the elevation of dopamine induced by nicotine in brain reward area. Nicotine 106-114 cannabinoid receptor 1 Homo sapiens 4-7 25859226-3 2015 The CB1 receptor inverse agonist/antagonist rimonabant (also known as SR141716) was effective to decrease nicotine-taking and nicotine-seeking in rodents, as well as the elevation of dopamine induced by nicotine in brain reward area. Nicotine 126-134 cannabinoid receptor 1 Homo sapiens 4-7 25859226-3 2015 The CB1 receptor inverse agonist/antagonist rimonabant (also known as SR141716) was effective to decrease nicotine-taking and nicotine-seeking in rodents, as well as the elevation of dopamine induced by nicotine in brain reward area. Nicotine 126-134 cannabinoid receptor 1 Homo sapiens 4-7 27453054-0 2016 Cannabinoid receptor 1 (CNR1) gene variant moderates neural index of cognitive disruption during nicotine withdrawal. Nicotine 97-105 cannabinoid receptor 1 Homo sapiens 0-22 27453054-0 2016 Cannabinoid receptor 1 (CNR1) gene variant moderates neural index of cognitive disruption during nicotine withdrawal. Nicotine 97-105 cannabinoid receptor 1 Homo sapiens 24-28 27453054-3 2016 Variation on the cannabinoid receptor 1 gene (CNR1) has been related to nicotine dependence, and CNR1 antagonists may increase attention and memory functioning. Nicotine 72-80 cannabinoid receptor 1 Homo sapiens 17-39 27453054-3 2016 Variation on the cannabinoid receptor 1 gene (CNR1) has been related to nicotine dependence, and CNR1 antagonists may increase attention and memory functioning. Nicotine 72-80 cannabinoid receptor 1 Homo sapiens 46-50 27453054-4 2016 We targeted CNR1 variants as moderators of a validated neural marker of nicotine withdrawal-related cognitive disruption. Nicotine 72-80 cannabinoid receptor 1 Homo sapiens 12-16 24140878-4 2014 A "bench to bedside strategy" was initially used to develop cannabinoid CB1 receptor antagonists for the treatment of nicotine addiction. Nicotine 118-126 cannabinoid receptor 1 Homo sapiens 72-75 23169348-1 2013 Cannabinoid-1 receptors (CB(1)) have an important role in nicotine reward and their function is disrupted by chronic nicotine exposure, suggesting nicotine-induced alterations in endocannabinoid (eCB) signaling. Nicotine 58-66 cannabinoid receptor 1 Homo sapiens 25-30 23169348-1 2013 Cannabinoid-1 receptors (CB(1)) have an important role in nicotine reward and their function is disrupted by chronic nicotine exposure, suggesting nicotine-induced alterations in endocannabinoid (eCB) signaling. Nicotine 117-125 cannabinoid receptor 1 Homo sapiens 0-23 23169348-1 2013 Cannabinoid-1 receptors (CB(1)) have an important role in nicotine reward and their function is disrupted by chronic nicotine exposure, suggesting nicotine-induced alterations in endocannabinoid (eCB) signaling. Nicotine 117-125 cannabinoid receptor 1 Homo sapiens 25-30 23169348-1 2013 Cannabinoid-1 receptors (CB(1)) have an important role in nicotine reward and their function is disrupted by chronic nicotine exposure, suggesting nicotine-induced alterations in endocannabinoid (eCB) signaling. Nicotine 117-125 cannabinoid receptor 1 Homo sapiens 0-23 23169348-1 2013 Cannabinoid-1 receptors (CB(1)) have an important role in nicotine reward and their function is disrupted by chronic nicotine exposure, suggesting nicotine-induced alterations in endocannabinoid (eCB) signaling. Nicotine 117-125 cannabinoid receptor 1 Homo sapiens 25-30 21412887-1 2011 BACKGROUND: Selective type 1 cannabinoid (CB1) receptor antagonists may assist with smoking cessation by restoring the balance of the endocannabinoid system, which can be disrupted by prolonged use of nicotine. Nicotine 201-209 cannabinoid receptor 1 Homo sapiens 42-45 22046326-8 2011 Overall, our results suggest that genetic variants potentially involved in nicotine metabolization (mainly, CYP2A6 polymorphisms) are those showing the strongest association with smoking-related phenotypes, as opposed to genetic variants influencing the brain effects of nicotine, e.g., through nicotinic acetylcholine (CHRNA5), serotoninergic (HTR2A), opioid (OPRM1) or cannabinoid receptors (CNR1). Nicotine 75-83 cannabinoid receptor 1 Homo sapiens 394-398 17592508-1 2007 Cannabinoid CB1 receptor antagonists are novel therapeutics with potential for the treatment of a number of conditions including obesity, nicotine addition and metabolic syndrome. Nicotine 138-146 cannabinoid receptor 1 Homo sapiens 12-15 18606954-0 2008 Cannabinoid receptor 1 gene association with nicotine dependence. Nicotine 45-53 cannabinoid receptor 1 Homo sapiens 0-22 18606954-4 2008 OBJECTIVE: To test the hypothesis that the CNR1 gene is associated with nicotine dependence. Nicotine 72-80 cannabinoid receptor 1 Homo sapiens 43-47 18606954-14 2008 CONCLUSION: Variants and haplotypes in the CNR1 gene may alter the risk for nicotine dependence, and the associations are likely sex specific. Nicotine 76-84 cannabinoid receptor 1 Homo sapiens 43-47 15904723-1 2005 The present study shows that the selective cannabinoid CB1 receptor antagonist SR141716A attenuated responding for both nicotine- and sucrose-associated stimuli in a long-term extinction-reinstatement model. Nicotine 120-128 cannabinoid receptor 1 Homo sapiens 55-58